Oral Administration of Probiotic Escherichia coli after Birth Reduces Frequency of Allergies and Repeated Infections Later in Life (after 10 and 20 Years)

  title={Oral Administration of Probiotic Escherichia coli after Birth Reduces Frequency of Allergies and Repeated Infections Later in Life (after 10 and 20 Years)},
  author={R{\'a}ja Lodinov{\'a}-Ž{\'a}dn{\'i}kov{\'a} and Bożena Cukrowska and Helena Tlaskalova-Hogenova},
  journal={International Archives of Allergy and Immunology},
  pages={209 - 211}
Background: The development of allergies is a complex in which both composition and influence of the intestinal flora play an important role. We observed in earlier studies that the presence of an orally administered probiotic Escherichia coli strain in the intestine stimulated both a serum and local antibody response, decreased the presence of pathogens, the number of infections and the need for antibiotics. Methods: The preventive effect of oral colonization after birth with a probiotic E… 

Tables from this paper

Prevention of Allergy in Infants of Allergic Mothers by Probiotic Escherichia coli

After birth, targeted colonization of the intestine by a probiotic E. coli strain can be an effective means of allergy prevention in infants of allergic mothers.

Effect of early postnatal supplementation of newborns with probiotic strain E. coli O83:K24:H31 on allergy incidence, dendritic cells, and microbiota

Early postnatal EcO83 supplementation appears to lower allergy incidence in children of AMs and the beneficial effect of EcO 83 is mediated via modulation of DC functional capacities without impacting the microbiota composition.

Administration of the Probiotic Escherichia coli Strain A0 34/86 Resulted in a Stable Colonization of the Human Intestine During the First Year of Life

Probiotic E. coli A0 34/86 successfully colonized the intestinal tract of an infant and became resident during the first year of life.

The role of gut microbiota in the pathogenesis and management of allergic diseases.

Clinical trial addressing the use of probiotics in the context of allergic disorders, have been conducted in children, but currently, no conclusive item may be drawn.

Probiotics for the young and the not so young

By reversing the changes in bowel flora which occur with age comes the prospect of rejuvenating ageing immune systems, preventing Clostridium difficile infections and bowel cancer, thereby fulfilling the early promise of prolongation of life.

Probiotics in Treatment and/or Prevention of Allergies

It has been shown that alterations in the intestinal microbiota can influence mucosal immunity and reduced family size and a reduction in childhood infections have reduced the exposure to microbes, which plays a crucial role in the maturation of the host immune system during the first years of life.

Effects of Probiotics and Prebiotics Antiallergic Effects of Probiotics 1 , 2

The hygiene hypothesis suggests that insufficient or aberrant exposure to environmental microbes is one of the causes of the development of allergy.

Differences in Developing Intestinal Microbiota between Allergic and Non-Allergic Infants: A Pilot Study in Japan

The population of Bacteroidaceae was significantly higher in the allergic group at the ages of 1 month and 2 months than in the non-allergic group, while no statistically significant difference was observed for the other bacterial populations.

Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics.

Certain probiotics may also reduce the risk of various symptoms of respiratory tract infections in adults and children, including ear, nose, and throat infections, although data is currently far too limited to distill any clinical recommendations in this area.



The antibody response in infants after colonization of the intestine with E. coli O83. Artificial colonization used as a prevention against nosocomial infections.

In this study, two groups of infants were observed: healthy full term infants colonized with E. coli O83 (Group A), in which antibody responses against the O83 antigen in serum, saliva, and stool were monitored to determine whether the common mucosal immune system was triggered.

Specific Proliferative and Antibody Responses of Premature Infants to Intestinal Colonization with Nonpathogenic Probiotic E. coli Strain Nissle 1917

It is concluded that the oral application of E. coli Nissle 1917 after birth significantly stimulates specific humoral and cellular responses and simultaneously induces nonspecific natural immunity.

Probiotics in primary prevention of atopic disease: a randomised placebo‐controlled trial.

Gut microflora might be a hitherto unexplored source of natural immunomodulators and probiotics, for prevention of atopic disease in children at high risk.

Implantation and in vivo antagonistic effects of antibiotic-susceptible Escherichia coli strains administered to premature newborns.

Two antibiotic-susceptible and non-pathogenic Escherichia coli strains were administered to hospitalized premature infants in order to protect them from intestinal colonization by hospital-acquired

The Antibody Response in Breast-Fed and Non-Breast-Fed Infants after Artificial Colonization of the Intestine with Escherichia coli 083

The results suggest that the mucosal immune system of the newborn infant can be triggered early to produce specific antibodies against bacteria colonizing the intestine.

Mucosal Immunity: Its Role in Defense and Allergy

Characteristic features of mucosal immunity distinguishing it from systemic immunity are: strongly developed mechanisms of innate defense, the existence of characteristic populations of unique types of lymphocytes, colonization of the mucosal and exocrine glands by cells originating from the mucosa organized tissues (‘common mucosal system’) and preferential induction of inhibition of the responses to nondangerous antigens (mucosal tolerance).